Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
Uroscan
Mark Emberton
Has overspecialization in
prostate cancer helped or
hindered progress in its
diagnosis and treatment?
Despite more elaborate
and expensive techniques,
treatment is still associated
with too much toxicity. It also
makes little economic sense
and is unsustainable. Even the
management of prostate cancer
is filled with great uncertainty
and lacks the strategies
employed to treat other types
of cancer. How can prostate
cancer be put on the same
track as breast or renal cancer
in terms of precision diagnosis
and focused therapy? Such
questions are at the forefront
of research being conducted
by Mark Emberton, reader in
interventional oncology at
University College London,
divisional clinical director of its
hospitals Cancer Services and
BJUI
UROSCAN
Additional Reading
Ahmed HU, Moore C,
Emberton M. Minimallyinvasive technologies in
uro-oncology: The role
of cryotherapy, HIFU and
photodynamic therapy
in whole gland and focal
therapy of localized prostate
cancer. Surg Oncol 2009; 18:
219-232
Ahmed HU, Zacharakis E,
Dudderidge T et al. Highintensity-focused ultrasound
in the treatment of primary
prostate cancer: The first
UK series. Br J Cancer 2009;
101: 19-26
Moore CM, Pendse D,
Emberton M. Photodynamic
therapy for prostate cancer
a review of current status
and future promise. Nat Clin
Pract Urol 2009; 6: 18-30
UROSCAN
Clinical Trial
Title:
STUDY OF GLOBAL COAGULATION TESTS IN PATIENTS WITH
PAROXYSMAL NOCTURNAL HAEMOGLOBINURIA
Protocol ID:
NCT01020188
Summary:
As a rare disease, paroxysmal nocturnal haemaoglobinuria
(PNH) results in the breakdown of red blood cells, causes
bone marrow failure and is associated with an increased
risk of blood clots. Treatment normally consists of blood
transfusions and blood thinners for those with blood clots.
Eculizumab is now standard for patients who require reg
ular blood transfusions; it prevents the breakdown of red
blood cells. The investigators plan to use specialised blood
tests to assess the stickiness of the blood before starting
eculizumab treatment and monthly after starting treat
ment. They will compare these tests with standard tests of
clotting. The primary outcome measure is to establish the
role of thrombin generation in assessing the prothrom
botic phenotype of PNH.
ELIGIBILITY:
Patients may be male or female and 18 years of age or
older. All must have PNH with the presence of a PNH
clone. Patients on long-term anticoagulation therapy for
previous venous thrombosis are excluded. The study is ex
pected to enroll 60 participants.
LOCATIONS AND CONTACTS:
Dupe Elebute, MB, MD, Kings College Hospital NHS Trust,
London, United Kingdom, 02032995761, dupe.elebute@
nhs.net.
JOURNAL
UROSCAN
In this issue...
Urological Oncology
REPEATED BIOPSYING HELPFUL IN PENILE CARCINOMA P1121